| 000 | 03641cam a2200385Ii 4500 | ||
|---|---|---|---|
| 988 | _aSpringer_Medicine_2017 | ||
| 999 |
_c95810 _d95810 _x1 |
||
| 001 | 95810 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230102112722.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 170417s2017 sz a o 000 0 eng d | ||
| 020 |
_a3319535609 _q(electronic bk.) |
||
| 020 |
_a9783319535609 _q(electronic bk.) |
||
| 020 | _z3319535587 | ||
| 020 |
_z9783319535586 _q(print) |
||
| 040 |
_aN$T _cN$T _dGW5XE _dEBLCP _dN$T _dYDX _dOCLCF _dUAB _dESU _dAZU _dUPM _dIOG _dCOO _dOTZ _dVT2 _dOCLCQ _dU3W _dES-MaUEC _bspa |
||
| 050 | 4 |
_aRC280.L8 _b2017 EB |
|
| 245 | 0 | 0 |
_aAsbestos and mesothelioma _cJoseph R. Testa, editor. |
| 264 | 1 |
_aCham, Switzerland _bSpringer _c2017. |
|
| 300 |
_a1 recurso en línea (viii, 407 páginas) _bilustraciones (algunas a color) |
||
| 336 |
_aTexto _btxt _2rdacontent |
||
| 337 |
_aelectrónico _bc _2rdamedia |
||
| 338 |
_arecurso electrónico _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF _2rda |
||
| 490 | 0 | _aCurrent cancer research | |
| 500 | _aSpringerLink | ||
| 505 | 0 | _a1. Malignant Mesothelioma -- An Asbestos Legacy -- 2. Asbestos and Fibrous Erionite -- 3. Epidemiology of Mesothelioma -- 4. Malignant Pleural Mesothelioma: History, Controversy and Future of a Man-Made Epidemic -- 5. Communities at High Risk in the Third Wave of Mesothelioma -- 6. Mesothelioma Pathology -- 7. Asbestos-Induced Inflammation in Malignant Mesothelioma and Other Lung Diseases -- 8. Germline and Somatic Mutations in Human Mesothelioma and Lessons from Asbestos-Exposed Genetically Engineered Mouse Models -- 9. Gene Signature of Malignant Pleural Mesothelioma -- 10. Cell Signaling and Epigenetic Mechanisms in Mesothelioma -- 11. 3D Models of Mesothelioma in the Study of Mechanisms of Cell Survival -- 12. Biomarkers of Response to Asbestos Exposure -- 13. Surgery Approaches in Mesothelioma -- 14. Radiotherapy and Photodynamic Therapy for Malignant Pleural Mesothelioma -- 15. Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma -- 16. Immunotherapeutic Approaches to Mesothelioma -- 17. Challenges Facing Mesothelioma Patients and Their Families: Medical/Legal Intersections -- 18. The Patient's Experience of Malignant Mesothelioma. | |
| 520 | 3 | _aThis volume is comprised of a multidisciplinary assessment of the interplay between asbestos and cancer as well as new research about the biology and treatment of malignant mesothelioma. Chapters on the various types of asbestos and other mineral fibers, epidemiology, history and future of asbestos-related diseases are included. Other reviews present new information about the role of asbestos-related inflammation and genetic factors, including the role of inherited mutations of BAP1, in mesothelioma causation, as well as recent research about gene signatures, cell signaling, and epigenetic mechanisms in asbestos-related diseases. Other chapters provide updates of novel disease biomarkers and prevention, mechanistic lesson from genetically engineered mouse and 3-D models of mesothelioma tumorigenesis and therapeutic resistance. Also included are up-to-date reviews of surgical, molecularly targeted chemotherapeutic, and immunotherapeutic approaches for mesothelioma as well as an overview of legal issues. | |
| 650 | 7 |
_aPulmones _xCáncer _2embne _9168954 |
|
| 700 | 1 |
_aTesta, Joseph R., _eeditor literario |
|
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-53560-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 |
_2lcc _cLE |
||
| 998 |
_b02/2018 _dz _e- _zSI |
||